Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 74, Issue 5, Pages 836-842Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-202972
Keywords
-
Categories
Funding
- 'Association Rhumatisme et Travail' (Rheumatology Department, Lariboisiere Hospital, Paris, France)
Ask authors/readers for more resources
Background Gout therapy includes xanthine oxidase inhibitors (XOI) and colchicine, which have both been associated with decreased cardiovascular risk. However, their effects on major cardiac events, such as myocardial infarction (MI), need to be investigated further. Objectives To investigate whether XOIs and colchicine are associated with decreased risk of MI. Methods This case-control study compared patients with first-ever MI and matched controls. Cases were recruited from the Pharmacoepidemiological General Research on MI registry. Controls were selected from a referent population (n= 8444) from general practice settings. Results The study sample consisted of 2277 MI patients and 4849 matched controls. Use of allopurinol was reported by 3.1% of cases and 3.8 of controls, and 1.1% of cases and controls used colchicine. The adjusted OR (95% CI) for MI with allopurinol use was 0.80 (0.59 to 1.09). When using less stringent matching criteria that allowed for inclusion of 2593 cases and 5185 controls, the adjusted OR was 0.73 (0.54 to 0.99). Similar results were found on analysis by sex and hypertension status. Colchicine used was not associated with a decreased risk of MI (aOR= 1.17 (0.70 to 1.93)). Conclusions Allopurinol may be associated with a reduced risk of MI. No decreased risk of MI was found in colchicine users. Besides its urate-lowering property, allopurinol might have a cardioprotective effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available